Sex, Not Age, Predicts Weight Loss Outcomes With Tirzepatide: A Retrospective Analysis
Authors' conclusion
Sex, but not age, predicted weight loss with tirzepatide among individuals using the medication continuously for ≥ 12 months.
Study context
- Population
- Adults with overweight or obesity who initiated tirzepatide at Mayo Clinic (June 2022–May 2024) and completed ≥ 12 months of continuous therapy; 57% women, mean age 56 ± 11 years
- Participants
- 1,039 adults
- Exposure
- Women vs men; age groups ≤ 45, 46-59, ≥ 60 years
- Outcome
- Total body weight loss percentage (TBWL%), stratified by sex and age groups
- Follow-up
- 15 months
Methodological detailsreal-world clinical practice, single-centre
- Real-world clinical practice
- Single-centre
Main finding
As reported in the abstract
TBWL%
Women vs Men: P < 0.001 · ≤ 45 years vs ≥ 60 years: P = 0.024
Observational data: associations, not effects.
Further findings
Independent predictors of weight loss (multivariable analyses)
- Greater weight loss independently associated with female sex, absence of T2D, no prior obesity medication use, no concomitant weight gain-promoting medications, and higher tirzepatide dosage
- Age was not an independent predictor
Original publication
Sex, Not Age, Predicts Weight Loss Outcomes With Tirzepatide: A Retrospective Analysis. Obesity (Silver Spring). Published 14 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →